

John E. Flaherty
Jonathan M.H. Short
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

*Attorneys for Plaintiffs/Counterclaim-Defendants
AstraZeneca AB, Aktiebolaget Hässle,
AstraZeneca LP, KBI Inc. and KBI-E Inc.*

Of Counsel:
Errol B. Taylor
Fredrick M. Zullo
MILBANK, TWEED, HADLEY
& McCLOY LLP
1 Chase Manhattan Plaza
New York, New York 10005-1413
(212) 530-5000

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

ASTRAZENECA AB; AKTIEBOLAGET
HÄSSLE; ASTRAZENECA LP; KBI INC.;
and KBI-E INC.,

Plaintiffs and
Counterclaim-Defendants
v.

HANMI USA, INC., HANMI
PHARMACEUTICAL CO., LTD., HANMI
FINE CHEMICAL CO., LTD, and HANMI
HOLDINGS CO., LTD.

Defendants and
Counterclaim-Plaintiffs.

Civil Action No. 3:11-CV-00760-JAP-TJB

Judge Joel A. Pisano
Magistrate Judge Tonianne J. Bongiovanni

**ASTRAZENECA’S DISCLOSURE OF ASSERTED CLAIMS PURSUANT
TO N.J. LOC. PAT. R. 3.6(B)**

Plaintiffs AstraZeneca AB, Aktiebolaget Hässle, AstraZeneca LP, KBI Inc. and KBI-E Inc. (collectively, “AstraZeneca”) assert pursuant to N.J. Loc. Pat. R. 3.6(b) that Hanmi USA, Inc., Hanmi Pharmaceutical Co., Ltd., Hanmi Fine Chemical Co., Ltd, and Hanmi Holdings Co., Ltd. (collectively, “Hanmi”) has infringed, continues to infringe and/or will infringe the following claims of the patents-in-suit (U.S. Patent No. 5,714,504 (the “’504 Patent”) and U.S. Patent No. 5,877,192 (the “’192 Patent”):

Under 35 U.S.C. § 271(e)(2):

- ’504 Patent claims 1-2, 4, and 6-7;
- ’192 Patent claims 1-7, 10-19, and 21-23;

Under 35 U.S.C. § 271(a):

- ’504 Patent claims 1-2, 4, and 6-7;
- ’192 Patent claims 1-7, 10-19, and 21-23;

Under 35 U.S.C. § 271(b):

- ’504 Patent claims 1-2, 4, and 6-7;
- ’192 Patent claims 1-7, 10-19 and 21-23

Under 35 U.S.C. § 271(c):

- ’504 Patent claims 1-2, 4, and 6-7;

- '192 Patent claims 1-7, 10-19, and 21-23.

Under 35 U.S.C. § 271(g):

- '192 Patent claims 12-19 and 21-22;

AstraZeneca reserves the right to modify the patent claims asserted in this case if circumstances warrant such modification, including but not limited to if the Court denies AstraZeneca's pending motion to strike and/or dismiss certain Hanmi defenses and counterclaims, (D.I. 16), if AstraZeneca learns additional facts during discovery indicating assertion of additional claims is warranted, and/or if new parties are added to the litigation.

Respectfully submitted,

Dated: May 18, 2011

By: s/John E. Flaherty
John E. Flaherty
Jonathan M.H. Short
McCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, New Jersey 07102
(973) 622-4444

Attorneys for Plaintiffs
ASTRAZENECA AB,
AKTIEBOLAGET HÄSSLE,
ASTRAZENECA LP, KBI INC.
and KBI-E INC.

Of Counsel:
Errol B. Taylor
Fredrick M. Zullo

MILBANK, TWEED, HADLEY
& McCLOY LLP
1 Chase Manhattan Plaza
New York, New York 10005-1413
(212) 530-5000

CERTIFICATE OF SERVICE

I hereby certify that on May 18, 2011, I caused a copy of the foregoing **ASTRAZENECA'S CONTINGENT DISCLOSURE OF ASSERTED CLAIMS PURSUANT TO N.J. LOC. PAT. R. 3.6(b)** to be served upon the following counsel by Federal Express and electronic mail:

Allyn Z. Lite, Esq.
Lite DePalma Greenberg, LLC
Two Gateway Center, 12th Floor
Newark, NJ 07102

Renita S. Rathinam, Esq.
Sughrue Mion PLLC
2100 Pennsylvania Avenue, NW Suite 800
Washington, District of Columbia 20037-3213

By: s/John E. Flaherty
John E. Flaherty